GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » 3-Year RORE %

Arch Biopartners (TSXV:ARCH) 3-Year RORE % : -27.43% (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Arch Biopartners's 3-Year RORE % for the quarter that ended in Dec. 2024 was -27.43%.

The industry rank for Arch Biopartners's 3-Year RORE % or its related term are showing as below:

TSXV:ARCH's 3-Year RORE % is ranked worse than
68.31% of 1376 companies
in the Biotechnology industry
Industry Median: -9.955 vs TSXV:ARCH: -27.43

Arch Biopartners 3-Year RORE % Historical Data

The historical data trend for Arch Biopartners's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners 3-Year RORE % Chart

Arch Biopartners Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.46 -12.03 -45.00 34.38 8.33

Arch Biopartners Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Dec24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.38 42.68 56.63 8.33 -27.43

Competitive Comparison of Arch Biopartners's 3-Year RORE %

For the Biotechnology subindustry, Arch Biopartners's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's 3-Year RORE % falls into.



Arch Biopartners 3-Year RORE % Calculation

Arch Biopartners's 3-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.024--0.055 )/( -0.113-0 )
=0.031/-0.113
=-27.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 3-year before.


Arch Biopartners  (TSXV:ARCH) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Arch Biopartners 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners Business Description

Traded in Other Exchanges
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.